Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O95876
UPID:
FRITZ_HUMAN
Alternative names:
Bardet-Biedl syndrome 15 protein; WD repeat-containing and planar cell polarity effector protein
Alternative UPACC:
O95876; Q53RW4; Q7Z2Z3
Background:
The WD repeat-containing and planar cell polarity effector protein fritz homolog plays a pivotal role in the planar cell polarity signaling pathway, crucial for ciliogenesis and collective cell movements. It acts as a core component of the CPLANE complex, facilitating the recruitment of IFT-A proteins to basal bodies.
Therapeutic significance:
Linked to Bardet-Biedl syndrome 15 and congenital heart defects, understanding the role of this protein could open doors to potential therapeutic strategies for these conditions.